not tagged
Vertex pharmaceuticals,CRISPR therapeutics AG
[]
#genetherapy for thalassemia !
exciting month with the #eha2022 &amp; review for . 95% reduction vs 89% reduction transfusion. risk of insertional mutagenesis a major consideration moving forward esp.given a choice when both get approved. 
Hematologist-Oncologist, Scientist, International Health Expert.
Media contributor ABC news,AAJ Tak.
Presidential ?? awardee.
Opinions personal.